Jaguar Health 관리

관리 기준 확인 3/4

Jaguar Health CEO는 Lisa Conte, Jun2013 에 임명되었습니다 의 임기는 11.17 년입니다. 총 연간 보상은 $ 815.85K, 70.6% 로 구성됩니다. 70.6% 급여 및 29.4% 보너스(회사 주식 및 옵션 포함). 는 € 226.79 가치에 해당하는 회사 주식의 0.002% 직접 소유합니다. 226.79. 경영진과 이사회의 평균 재임 기간은 각각 3.7 년과 6.4 년입니다.

주요 정보

Lisa Conte

최고 경영자

US$815.9k

총 보상

CEO 급여 비율	70.6%
CEO 임기	11.2yrs
CEO 소유권	0.002%
경영진 평균 재임 기간	3.7yrs
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Lisa Conte 의 보수는 Jaguar Health 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$36m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$816k	US$576k	-US$41m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$44m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$1m	US$603k	-US$47m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$3m	US$527k	-US$53m
Sep 30 2021	n/a	n/a	-US$50m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	US$1m	US$500k	-US$39m
Sep 30 2020	n/a	n/a	-US$35m
Jun 30 2020	n/a	n/a	-US$39m
Mar 31 2020	n/a	n/a	-US$45m
Dec 31 2019	US$1m	US$500k	-US$45m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$34m
Dec 31 2018	US$1m	US$480k	-US$32m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	-US$30m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	US$643k	US$440k	-US$22m

보상 대 시장: Lisa 의 총 보상 ($USD 815.85K )은 German 시장( $USD 474.54K ).

보상과 수익: Lisa 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Lisa Conte (65 yo)

11.2yrs

테뉴어

US$815,854

보상

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...

리더십 팀

이름	위치	테뉴어	보상	소유권
Lisa Conte	Founder	11.2yrs	US$815.85k	0.0021% € 226.8
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	2.4yrs	US$627.13k	0.00063% € 67.1
Jonathan Wolin	Chief of Staff	5.8yrs	US$562.79k	0.00059% € 62.8
Steven King	Chief of Sustainable Supply	9.9yrs	US$491.54k	0.00051% € 54.3
Carol Lizak	Chief Financial Officer	4.4yrs	데이터 없음	0.00030% € 31.9
Peter Hodge	Senior Director of Investor Relations	no data	데이터 없음	데이터 없음
Karen Brunke	Executive VP of Corporate & Business Development	2.9yrs	데이터 없음	데이터 없음
David Sesin	Chief Manufacturing Officer	no data	데이터 없음	데이터 없음
Ian Wendt	Chief Commercial Officer	3.7yrs	US$557.90k	데이터 없음
Massimo Radaelli	President of Jaguar International	less than a year	데이터 없음	데이터 없음
Catherine Collis	Senior Vice President of Growth Strategy	less than a year	데이터 없음	데이터 없음
Darlene Horton	Chief Medical Officer	no data	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: 1JA 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lisa Conte	Founder	11.2yrs	US$815.85k	0.0021% € 226.8
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	7.3yrs	US$627.13k	0.00063% € 67.1
James Bochnowski	Independent Chairman	10.5yrs	US$140.98k	0.00066% € 70.3
John Micek	Independent Director	8.3yrs	US$101.68k	0.00038% € 40.5
Anula Jayasuriya	Independent Director	2.1yrs	US$77.61k	0.00051% € 54.3
Jonathan Siegel	Independent Director	6.4yrs	US$104.18k	0.00042% € 44.7
Sandra Swain	Member of Scientific Advisory Board	1.6yrs	데이터 없음	데이터 없음
Kelly Shanahan	Scientific Advisory Board	1.4yrs	데이터 없음	데이터 없음
Stacey Tinianov	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음

6.4yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 1JA 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

Jaguar Health 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Recent updates

FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings released: US$0.058 loss per share (vs US$2.39 loss in 1Q 2023)

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.38 loss per share (vs US$8.83 loss in 3Q 2022)

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Financial position

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$8.82 loss in 2Q 2022)

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings released

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

New 90-day high: €0.40

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Revenue misses expectations

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health Receives Positive Nasdaq Listing Determination

New 90-day low: €0.24

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: €0.26

New 90-day low - €0.34

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령